Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Mouth Neoplasms 2Tobacco Use Disorder 1Pancreatic Adenocarcinoma 1Mouth Diseases 1Lichen Planus 1Leukokeratosis, Hereditary Mucosal 1Fanconi Anemia 1Erythroplasia 1

Interventions

Taxes 1Standard of Care 1Panitumumab 1Pancreaticoduodenectomy 1Optical Imaging 1Losartan 1Gemcitabine 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma × Optical Imaging × 90 days × Clear all
NCT03384238 2026-03-17

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

Stanford University

Phase 1/2 Recruiting
27 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡